Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma
Head & Neck · 2024
DOI: 10.1002/hed.27651 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2024. Verfasst von Ester Benaiges und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain. Hauptthemen laut MEDLINE: Survivin, Radiation Tolerance, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Salud Carlos III, Fundación Científica Asociación Española Contra el Cáncer, Ministerio de Ciencia e Innovación.
Abstract (Originalsprache)
Background
Metabolic reprogramming and abnormal glucose metabolism are hallmarks of head and neck squamous cell carcinoma (HNSCC). Certain oncogenes can promote cancer‐related metabolic changes, but understanding their crosstalk in HNSCC biology and treatment is essential for identifying predictive biomarkers and developing target therapies.
Methods
We assessed the value of survivin/BIRC5 as a radioresistance factor potentially modulated by glucose for predicting therapeutic sensitivity and prognosis of HNSCC in a cohort of 32 patients. Additionally, we conducted in vitro experiments to explore the role of survivin/BIRC5 in glucose metabolism concerning radiation response.
Results
Tumoral BIRC5 expression is associated with serum glucose and predicts locoregional disease‐free survival and lower BIRC5 mRNA levels are associated with better outcomes. Upregulation of BIRC5 by radiation depends on glucose levels and provokes a pro‐tumoral and radioresistant phenotype in surviving cells.
Conclusions
Survivin/BIRC5 might be independently associated with the risk of recurrence in patients with HNSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departament de Medicina i Cirurgia, Universitat Rovira i Virgili, Reus, Spain.
- Grup de Recerca en Diabetis i Malalties Metabòliques Associades (DIAMET), Institut d'Investigació Sanitària Pere Virgili (IISPV), Hospital Universitari Joan XXIII, Tarragona, Spain.
- CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)-Instituto de Salud Carlos III (ISCIII), Madrid, Spain.
- Departament d'Oncologia, Hospital Universitari Sant Joan, Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
- Unitat de Recerca en Lípids i Arteriosclerosi (URLA), Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira i Virgili, Reus, Spain.
- Servei d'Oncologia Radioteràpica, Hospital Universitari Sant Joan, Institut d'Investigació Sanitària Pere Virgili (IISPV), Reus, Spain.
ORCID-Profile: Isabel Vilaseca, Xavier León, Francesc Xavier Avilés-Jurado, Sonia Fernández-Veledo
Förderung
- Instituto de Salud Carlos III
- Fundación Científica Asociación Española Contra el Cáncer
- Ministerio de Ciencia e Innovación
- Universitat Rovira i Virgili
- Ramón y Cajal program
- Miguel Servet tenue track program
- Departament de Recerca i Universitats de la Generalitat de Catalunya
Zitieren
APA
Benaiges, E., Ceperuelo-Mallafré, V., Guaita, S., Maymó-Masip, E., Madeira, A., Gómez, D., Hernández, V., Vilaseca, I., Merma, C., León, X., Terra, X., Vendrell, J., Avilés-Jurado, F. X., & Fernández-Veledo, S. (2024). Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Head & Neck. https://doi.org/10.1002/hed.27651
Vancouver
Benaiges E, Ceperuelo-Mallafré V, Guaita S, Maymó-Masip E, Madeira A, Gómez D, et al. Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma. Head & Neck. 2024. doi:10.1002/hed.27651
BibTeX
@article{Benaiges2024,
author = {Benaiges, Ester and Ceperuelo-Mallafré, Victòria and Guaita, Sandra and Maymó-Masip, Elsa and Madeira, Ana and Gómez, David and Hernández, Victor and Vilaseca, Isabel and Merma, Carla and León, Xavier and Terra, Ximena and Vendrell, Joan and Avilés-Jurado, Francesc Xavier and Fernández-Veledo, Sonia},
title = {Survivin/ BIRC5 as a novel molecular effector at the crossroads of glucose metabolism and radioresistance in head and neck squamous cell carcinoma},
journal = {Head & Neck},
year = {2024},
doi = {10.1002/hed.27651}
}
EUVIMED